Levi & Korsinsky, LLP: Section 10(b) and Rule 10b-5 Claims Filed Against Ultragenyx Pharmaceutical
Shareholders Who Purchased RARE Stock During Class Period Urged to Review Options
NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that a securities class action has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE).
YOU MAY BE AFFECTED IF YOU:
- Purchased Ultragenyx stock between August 3, 2023 and December 26, 2025
- Lost money on your Ultragenyx investment
- Held shares through either the July 2025 or December 2025 corrective disclosures
Find out if you qualify or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com | (212) 363-7500.
The Federal Securities Law Framework
Section 10(b) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 prohibit making untrue statements of material facts or omitting material facts necessary to make statements not misleading. The action contends that Ultragenyx and certain officers violated these provisions through allegedly false and misleading statements about the Company's Phase III clinical studies.
Claims Pleaded in the Complaint
- Section 10(b) claims against the Company and individual defendants for allegedly making materially false and misleading statements
- Rule 10b-5 violations for allegedly employing devices, schemes, and artifices to defraud in connection with securities purchases and sales
- Section 20(a) control person claims against individual defendants who allegedly controlled the Company's public statements
- Scienter allegations based on defendants' positions and access to non-public information about study progress and risks
Procedural Posture and Class Certification
As pleaded, the action was filed in the United States District Court, Northern District of California on February 4, 2026. Plaintiffs allege that the market for RARE common stock was efficient and that the fraud-on-the-market doctrine establishes a presumption of reliance for class members.
"The PSLRA provides important protections for investors harmed by alleged securities violations," said Joseph E. Levi, Esq. "The extensive documentation of management's statements during earnings calls supports detailed examination of what executives knew when making representations to investors."
Learn more about this lawsuit or contact our attorneys at (212) 363-7500.
WHY LEVI & KORSINSKY
Ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors across the country. Motions for lead plaintiff must be filed with the Court by April 6, 2026.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
(212) 363-7500
jlevi@levikorsinsky.com
www.zlk.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
